Leibniz Institute for Immunotherapy
A research institute focused on developing cell-based immunotherapies for cancer, autoimmunity and chronic inflammation. Activities span basic discovery, preclinical translation (including genetic, epigenetic and pharmacologic reprogramming of immune cells), GMP-compliant manufacture of clinical-grade cell therapeutics, and clinical trial implementation with associated regulatory and immunomonitoring platforms.
Industries
Nr. of Employees
medium (51-250)
Leibniz Institute for Immunotherapy
Services
Technology transfer and licensing
IP protection, licensing agreements, material transfer negotiations and collaboration facilitation to translate research into commercial development.
Core laboratory services (NGS, FACS/flow cytometry, immune monitoring)
Centralized sequencing, cell-sorting and immune-monitoring platforms to support discovery and translational projects.
GCP and clinical translation support
Platforms to handle regulatory requirements, clinical trial preparation and conduct in collaboration with clinical partners and GMP facilities.
Technology transfer and licensing
IP protection, licensing agreements, material transfer negotiations and collaboration facilitation to translate research into commercial development.
Core laboratory services (NGS, FACS/flow cytometry, immune monitoring)
Centralized sequencing, cell-sorting and immune-monitoring platforms to support discovery and translational projects.
GCP and clinical translation support
Platforms to handle regulatory requirements, clinical trial preparation and conduct in collaboration with clinical partners and GMP facilities.
Expertise Areas
- Cell therapy development
- Preclinical translation of immune-cell therapeutics
- GMP manufacturing for cell therapeutics
- Clinical trial implementation and GCP compliance
Key Technologies
- Cell engineering and adoptive T-cell therapy
- Inducible expression systems in engineered cells
- Synthetic receptor/biosensor design for immune cells
- Next-generation sequencing (NGS)